TP53 and non-small cell lung carcinoma: A similar effect was seen in p53-WT H460 non-small-cell lung cancer cells [84], where treatment with a low concentration (7.9 μM) of another platinum-based anticancer drug, carboplatin, that caused approximately 50% loss of clonogenic potential in the CF assay caused very little apoptosis but a significant proportion of the cells displayed the enlarged/flattened morphology and SA-β-gal-positivity characteristic of TCS as well as increased levels of p53 and p21.